Search Results
Dec 11, 2025, 10:15 ET TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
October 13, 2025, Tvardi Therapeutics, Inc. saw its shares plummet over 80% after disappointing preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis. The study was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function. After
More news about: Faruqi & Faruqi, LLP
Dec 09, 2025, 08:00 ET TETRA TECHNOLOGIES, INC. TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
SPRING, Texas, Dec. 9, 2025 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE: TTI) announced that its senior management will be participating in the following investor conferences.Jefferies 11th Annual Virtual
More news about: TETRA Technologies, Inc.
Dec 04, 2025, 10:28 ET INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
Immunotherapeutics saw its shares plummet over 80% on Monday October 13, 2025 after disappointing preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis. The study was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function. After
More news about: Faruqi & Faruqi, LLP
Nov 30, 2025, 09:46 ET TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
October 13, 2025, Tvardi Therapeutics, Inc. saw its shares plummet over 80% after disappointing preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis. The study was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function. After
More news about: Faruqi & Faruqi, LLP
Nov 25, 2025, 17:31 ET Mitochondrial Myopathies Market to Register Stunning Growth at a CAGR of 26.5% During the Forecast Period (2025-2034) Driven by Recent Approvals and Pipeline Advancements and Rising Awareness | DelveInsight
therapies such as Sonlicromanol (Khondrion; redox modulator), KL1333 (Pharming; NAD?/NADH modulation), Zagociguat (Tisento/Cyclerion; sGC stimulation), TTI-0102 (Thiogenesis; thiol-based mitochondrial support), and others will also propel the mitochondrial myopathies market growth.LAS
More news about: DelveInsight Business Research, LLP
Nov 21, 2025, 10:08 ET TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
October 13, 2025, Tvardi Therapeutics, Inc. saw its shares plummet over 80% after disappointing preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis. The study was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function. After
More news about: Faruqi & Faruqi, LLP
Nov 14, 2025, 10:31 ET SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Tvardi
October 13, 2025, Tvardi Therapeutics, Inc. saw its shares plummet over 80% after disappointing preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis. The study was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function. After
More news about: Faruqi & Faruqi, LLP
Nov 07, 2025, 09:00 ET HanchorBio Presents Two Late-Breaking Abstracts at the Society for Immunotherapy of Cancer 2025 Demonstrating Best-in-Class Potential of HCB101 in Advanced Cancers
safety or efficacy challenges, leading to discontinuations or halted collaborations. Second-generation wild-type SIRPα fusions, such as maplirpacept (TTI-622), improved safety but did not deliver sufficient efficacy in solid tumors, limiting their adoption. IgG1-based fusions attempted to boost immune activation
More news about: HanchorBio Inc.
Nov 03, 2025, 10:19 ET INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
Therapeutics, Inc. saw its shares plummet over 80% on Monday October 13, 2025 after disappointing preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis. The study was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function. After
More news about: Faruqi & Faruqi, LLP
Oct 28, 2025, 09:31 ET TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
Immunotherapeutics saw its shares plummet over 80% on Monday October 13, 2025 after disappointing preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis. The study was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function. After
More news about: Faruqi & Faruqi, LLP
Oct 27, 2025, 08:00 ET TETRA TECHNOLOGIES, INC. ANNOUNCES CFO TRANSITION WITH PLANNED RETIREMENT OF ELIJIO SERRANO AND APPOINTMENT OF MATT SANDERSON
WOODLANDS, Texas, Oct. 27, 2025 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE: TTI) announced today that Elijio Serrano has notified the Company of his intention to retire as Senior Vice-President and Chief Financial Officer, effective
More news about: TETRA Technologies, Inc.
Oct 23, 2025, 13:05 ET Faruqi & Faruqi Reminds Tvardi Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 3, 2025 - TVRD
October 13, 2025, Tvardi Therapeutics, Inc. saw its shares plummet over 80% after disappointing preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis. The study was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function. After
More news about: Faruqi & Faruqi, LLP
Oct 15, 2025, 10:02 ET TVRD SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
October 13, 2025, Tvardi Therapeutics, Inc. saw its shares plummet over 80% after disappointing preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis. The study was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function. After
More news about: Faruqi & Faruqi, LLP
Sep 25, 2025, 12:00 ET TETRA TECHNOLOGIES, INC. OUTLINES ONE TETRA 2030 GROWTH STRATEGY FOR ENHANCED SHAREHOLDER VALUE AT NYSE INVESTOR DAY
Sept. 25, 2025 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE: TTI) this morning outlined a path towards reshaping the Company by capitalizing on several key emerging growth initiatives that are positioned to evolve
More news about: TETRA Technologies, Inc.
Sep 25, 2025, 08:55 ET NYSE Content Advisory: Pre-Market Update + President of South Korea rings Opening Bell
President of South Korea, rings the Opening Bell Closing BellTetra Technologies (NYSE: TTI) celebrates ONE TETRA – The Path to 2030
More news about: New York Stock Exchange